Editorial scope: This page explains mushroom research and its limits. It does not sell a product. It is not medical advice.
By MushroomHealthBenefits.com Research & Editorial Team
Last reviewed: August 28, 2026
Research Profile
- Species: Reishi (Ganoderma lucidum)
- Human evidence grade: Very low certainty
- Best-supported conclusion: Reishi has many human trials, but the newest GRADE review found the certainty too low for strong health promises.
- Key limit: The form, amount, study group, and study length can vary.
What Reishi is
Reishi is the common name used here for Ganoderma lucidum. The science name helps you check the exact species.
Food, powder, mycelium, fruiting body, tea, and extract are not the same form. Our evidence grading policy explains how we grade each claim.
What human research says
A 2025 GRADE systematic review pooled 17 randomized trials with 971 participants. It found no clear effect for many cardiovascular and metabolic measures, and rated the certainty of the evidence very low.
Plain-language grade: Very low certainty. The topic needs more good human studies. The current work does not support a certain result.
What laboratory and animal work can tell us
Lab and animal work can find compounds and ideas to test. It cannot show what will happen in a person.
A cell or animal result stays preclinical. A good human study must test the same form and a useful outcome.
Traditional use and food history
Reishi has a long record in East Asian traditional practice. Traditional use can guide research questions, but it cannot replace controlled human evidence.
Form and dose context
Trials have used different doses, treatment periods, populations, and Ganoderma preparations. A studied extract cannot be treated as equal to every Reishi food or retail formula.
Start with the label. Check the species, mushroom part, form, daily amount, study group, and study length. If those facts do not match, the study may not fit the label.
Safety, interactions and who should avoid it
Non-serious adverse events occurred in the reviewed trials. FDA advises discussing supplement use with a healthcare professional.
Your health history and medicine list matter. Read our medical disclaimer. Ask a skilled health professional for advice about you.
How to read benefit claims
- Prefer human trials over cell or animal findings.
- Check whether the studied form matches the form being discussed.
- Look for sample size, comparison group, study length, and adverse effects.
- Treat one small trial as an early signal, not a settled answer.
- Be cautious when a broad claim is built from a narrow clinical setting.
Use a simple check. Start with the full study. Find who took part. Find the form and amount.
Look for a control group. Note the study length. Read the harms. Read what did not change.
One study is a clue. It is not the last word. Results should be repeated by other teams.
Ask what was tested. Ask who took it. Ask how much they took. Ask how long they took it.
Good studies show both gains and misses.
Our editorial standards keep each benefit claim inside the research limit.
Primary and authoritative sources
- Research source 1: Ganoderma lucidum supplementation: a GRADE-assessed systematic review and meta-analysis. The 2025 review included 17 randomized trials and 971 participants, reported many null outcomes, and judged the evidence very uncertain.
- Research source 2: Ganoderma lucidum for cardiovascular risk factors. A systematic review found insufficient evidence to support Ganoderma lucidum for cardiovascular risk factors in people with type 2 diabetes.
The bottom line
Reishi has many human trials, but the newest GRADE review found the certainty too low for strong health promises.
This page is for general learning. It does not diagnose, treat, support, or prevent disease. It cannot replace advice from a qualified health professional.